Recombinant protein, nucleic acid molecule, recombinant bacteriophage and application thereof

By using recombinant proteins, nucleic acid molecules and recombinant phage technologies, combining targeted peptides and M13KE phages, the problem of poor protection effect of existing PEDV vaccines was solved, and efficiently induced antibody and T cell responses were achieved, which significantly improved the immune protection ability.

CN119751703AActive Publication Date: 2025-04-04SHANGHAI JIAOTONG UNIV
5 Cites 0 Cited by

Patent Information

Application Number
CN202411985306.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-31
Publication Date
2025-04-04
Estimated Expiration
2044-12-31

AI Technical Summary

Technical Problem

The protective effect of the existing PEDV vaccine is not ideal for epidemic strains. Inactivated vaccines are difficult to produce effective mucosal immunity. The intestinal stability and proliferation ability of the attenuated vaccines are reduced, and the protective power produced is limited.

Method used

Recombinant proteins, nucleic acid molecules and recombinant phages are used to bind to the dominant epitope of the PEDV S protein by targeting peptides BXT1 and BXT2, and M13KE phages are used as delivery vectors to induce the production of antigen-specific PEDVIgG antibodies and neutralizing antibodies.

Benefits of technology

Effectively induce mice to produce specific IgG antibodies, T cells and neutralizing antibodies against PEDV, significantly improving the immune protection ability to PEDV, and improving the practicality of vaccine production and marketing through dose-saving immune practices.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the field of biological medicine, in particular to a recombinant protein, a nucleic acid molecule, a recombinant bacteriophage and application thereof. The invention provides a recombinant protein with an amino acid sequence as shown in SEQ ID NO.6, a recombinant protein with an amino acid sequence as shown in SEQ ID NO.10 and application of the recombinant protein in preparation of vaccines. A vaccine prepared by injecting the recombinant protein can effectively prevent coronavirus infection. According to the invention, the PEDV S protein is selected as a candidate antigen for epitope design, two targeting peptides connected with the specific S protein epitope are selected, the M13KE phage is selected as a delivery carrier of the PEDV epitope, and animal experiments are utilized to evaluate the effect of the PEDV vaccine. The result shows that the lymphocyte of the vaccinated mouse shows an obvious proliferation reaction to the PEDV antigen; and the IFN-gamma level in the serum of the vaccinated mouse is obviously increased.
Need to check novelty before this filing date? Find Prior Art